Company profile
InVitro International
OTC: IVRO · Healthcare · Medical - Diagnostics & Research
#878 of 1,418 Healthcare companies by revenue54th-percentile growth
EA Score
76B+FH 86DQ —GM 61SS 49
v0.1 · 45/100 weight · provisional
↑ listing tenure, net margin · ↓ workforce scale, market scale
Methodology →Revenue TTM
$771.1k
Rev growth YoY (TTM)
-14.0%
Net income (FY)
$122.0k
Employees
5
as of 2026-08-25
Market cap
$1.8M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$878.9k$878.9k2025
Net income$122.0k$122.0k2025
Operating income$87.0k$87.0k2025
Total assets$2.0M$2.0M2025
Liabilities$348.2k$348.2k2025
Equity$1.7M$1.7M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is InVitro International’s revenue?
InVitro International booked $878.9k in FY2025 revenue, growing 8.3% year over year — about the middle of the pack among Healthcare companies we track, at a 13.9% net margin.
Peers · Healthcare
INDVR Brands Inc.——Quick-Med Technologies, Inc.——ProKidney Corp.41DProfile Solutions, Inc.——IGC Pharma, Inc.45DRallybio Corporation47DNeighbors
Orange →Key facts
CEOW. Richard Ulmer
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersPlacentia, CA
ExchangeOTC: IVRO
Employees5
IPO date1991-05-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.